Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review.

Oncotarget · 2017 · PMC5584287 · PMID 28881686

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

might not be significantno p-value reported

First, the difference in the mutational burden between SQ and non-SQ NSCLC might not be significant.

also in 673 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.